Abstract
In this article the design of hybrid molecules that covalently connect two distinct drug entities in one molecule, at least one part being a biologically active natural product will be discussed. In the quest for novel drug entities, the hybrid approach is a promising path to drug molecules that can effectively target multifactorial diseases including neurodegenerative disorders like Alzheimer's and Parkinson's diseases (AD and PD). The hybrid approach can also be used to optimize certain biological properties like affinity and selectivity, but also to gain novel biological activities distinct from the ones of the components.
Due to the high potential of natural products to exhibit pronounced biological activities, natural products have been one of the major sources of components in hybrid molecules. This review will cover their applications in developing drugs for neurodegenerative disorders, in the diverse field of anti-cancer agents (which represents the major application for natural products in medicinal chemistry), but also in miscellaneous areas of bioactive compounds including antioxidants, antimalarial drugs and estrogen-related hybrids to reach various therapeutic aims.
The unique tasks of hybrid molecule design will be addressed, such as describing suitable ways to chemically connect the drug components, how to use the approach to enhance biological activity with respect to both activity and selectivity and potential drawbacks of the hybrid approach. It will be shown that hybrids can be more than the sum of their components, but in many cases should be considered as pharmacological entities in their own respect.
Keywords: Alzheimer's disease, antioxidants, antitumor agents, cancer, hybrid molecules, natural products, neurodegenerative disorders, Parkinson's disease, multifactorial diseases, biological activities
Current Medicinal Chemistry
Title: Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond
Volume: 18 Issue: 10
Author(s): M. Decker
Affiliation:
Keywords: Alzheimer's disease, antioxidants, antitumor agents, cancer, hybrid molecules, natural products, neurodegenerative disorders, Parkinson's disease, multifactorial diseases, biological activities
Abstract: In this article the design of hybrid molecules that covalently connect two distinct drug entities in one molecule, at least one part being a biologically active natural product will be discussed. In the quest for novel drug entities, the hybrid approach is a promising path to drug molecules that can effectively target multifactorial diseases including neurodegenerative disorders like Alzheimer's and Parkinson's diseases (AD and PD). The hybrid approach can also be used to optimize certain biological properties like affinity and selectivity, but also to gain novel biological activities distinct from the ones of the components.
Due to the high potential of natural products to exhibit pronounced biological activities, natural products have been one of the major sources of components in hybrid molecules. This review will cover their applications in developing drugs for neurodegenerative disorders, in the diverse field of anti-cancer agents (which represents the major application for natural products in medicinal chemistry), but also in miscellaneous areas of bioactive compounds including antioxidants, antimalarial drugs and estrogen-related hybrids to reach various therapeutic aims.
The unique tasks of hybrid molecule design will be addressed, such as describing suitable ways to chemically connect the drug components, how to use the approach to enhance biological activity with respect to both activity and selectivity and potential drawbacks of the hybrid approach. It will be shown that hybrids can be more than the sum of their components, but in many cases should be considered as pharmacological entities in their own respect.
Export Options
About this article
Cite this article as:
Decker M., Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328355
DOI https://dx.doi.org/10.2174/092986711795328355 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Production of Retroviral Vectors: Review
Current Gene Therapy Gastric Inhibitory Polypeptide and its Receptor are Expressed in the Central Nervous System and Support Neuronal Survival
Central Nervous System Agents in Medicinal Chemistry Interactions Between Apo E and Amyloid Beta and their Relationship to Nutriproteomics and Neurodegeneration
Current Proteomics Dimebon Attenuates the Aβ-Induced Mitochondrial Permeabilization
Current Alzheimer Research The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury
Current Medicinal Chemistry Editorial [Hot Topic:Neurobiology Wakes Up for Research on Sleep Disorders: An Integration of Basic and Clinical Research(Executive Editor: Luigi De Gennaro)]
Current Pharmaceutical Design Epigenetics in Brain Tumors: HDACs Take Center Stage
Current Neuropharmacology Aromatherapy and the Central Nerve System (CNS): Therapeutic Mechanism and its Associated Genes
Current Drug Targets The AMP-Activated Protein Kinase: Role in Regulation of Skeletal Muscle Metabolism and Insulin Sensitivity
Mini-Reviews in Medicinal Chemistry Recent Developments in the Synthesis of Antitumor-active Glycyrrhetinic Acid Derivatives
Mini-Reviews in Organic Chemistry The Panomics Approach in Neurodegenerative Disorders
Current Medicinal Chemistry Clonal Expansion of Mitochondrial DNA Deletions and the Progression of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design